This review summarises and discusses the recent primary publication for a study examining once-daily single inhaler triple therapy consisting of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA)
and a long-acting β2-agonist (LABA) versus dual therapy (either ICS-LABA or LAMA-LABA) in patients with
chronic obstructive pulmonary disease (COPD; the IMPACT trial).
Independent commentary is provided by Professor Christine Jenkins, Head of the Respiratory Group at
The George institute for Global Health; Senior Staff Specialist in Thoracic Medicine at Concord Hospital,
Sydney; Clinical Professor and Head of Respiratory Discipline at University of Sydney; and Professor of
Respiratory Medicine at UNSW Sydney.
Please login below to download this issue (PDF)